Inflammatory arthritis as a result of immune checkpoint cancer therapy remains a pressing challenge for patients and ...

These patients will not have been treated with immune checkpoint inhibitors previously. The therapy will be evaluated as a ...

High-risk NMIBC is characterised by poor prognosis, with half of patients recurring despite effective treatment with the ...

A protein identified by researchers at UT Southwestern Medical Center may drive resistance to immune checkpoint inhibitors, a ...

A recent case report explains how epitope spread may cause immune checkpoint inhibitor (ICI)–associated bullous pemphigoid (BP). A separate research letter spotlights cases of partial ...

Neurological disorders, including neurosurgical conditions and various neurological diseases, are often associated with ...

Trials of IFx-Hu2.0 are initiating, looking to overcome checkpoint inhibitor resistance in Merkel cell carcinoma.

Predictors of longer postdiscontinuation progression-free survival include complete/partial response, longer treatment duration.

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

Investigator studied current treatment patterns and attrition rates in metastatic clear cell renal cell carcinoma using a large, US nationwide cohort.